After more than 30 years of development, antibody drugs have become an important part of the global pharmaceutical market. At present, the rapid growth of the macromolecular biopharmaceutical market (including recombinant protein drugs) has exceeded $1 billion. From the market performance in 2017, among the top 10 best-selling drugs in the world: in addition to the two small-molecule drugs, the other eight are macromolecular drugs, including 6 antibody drugs and 2 fusion proteins. Among them, the drug king “Humira†had sales of US$18.4 billion, and it has contributed a total of US$112 billion in sales to Abbvie for 16 years. In recent years, the emergence of novel tumor immunomodulatory antibody drugs (such as PD-1/PD-L1 blockers) has also brought about new therapeutic breakthroughs. Among them, the first therapeutic antibody against PD-1, Opdivo, developed by BMS, Top10 on the list of nearly $6 billion.
In the direction of drug research and development, the biomacromolecular drug market is highly concentrated, and the monopoly position is “transcendentalâ€. At the same time, the biopharmaceutical market is also cultivating many new opportunities and changes. The new targets and new mechanisms of action are emerging in an endless stream of research and development companies. There is much to be done in the pharmaceutical field. For every step of the biomacromolecular pharmaceutical development process, PerkinElmer offers a full range of detection technologies, instrument platforms, reagent supplies and related services covering molecular-cell-living-tissue.
For every step of the biomacromolecular pharmaceutical development process, PerkinElmer offers a full range of detection technologies, instrument platforms, reagent supplies and related services covering molecular-cell-living-tissue. Antibody screening for different libraries such as hybridomas, phage or human B cells, high-throughput multi-mode detection systems, multi-standard reagents (such as high-sensitivity disposable Alpha technology) and cell lines, high-content cell microscopy imaging systems, automation Sample processing workstations provide optimal high-throughput antibody screening and optimization at the molecular and cellular levels. For preclinical/clinical functional verification, safety evaluation and therapeutic effects of antibody drugs, systematic evaluation of molecular mechanisms, cell signaling pathways, tissue microenvironments and overall animal levels can be accomplished by means of biochemical detection and molecular imaging platforms. Automated capillary electrophoresis antibody analysis system and multi-mode detection for antibody quality, glycosylation, fragmentation/polymerization, charge heterogeneity and host cell residues in antibody process development and production quality control And professional kits can greatly reduce the technical cost of this link. In addition, with the advent of the medical big data era, the PerkinElmer Signal data mining and analysis system, combined with high-quality microscopic imaging technology and digital quantitative pathological intelligence algorithms, further accelerates the transformation from basic research to clinical practice.
The application will cover:
ï‚· High-throughput screening and optimization of in vitro antibodies ï‚· Functional evaluation and study of antibody in vitro ï‚· Evaluation of antibody therapy in vivo at living level ï‚· Clinical histopathological antibody diagnosis and treatment
For details, please click or scan the code to download a sample of Biomacromolecules Total Solutions:
http://cn.mikecrm.com/OYbuWWM
About PerkinElmer:
As the world's leading provider of scientific instruments and services, PerkinElmer is committed to creating a healthier world. Our business covers medical diagnostics, scientific research and analytical instruments. With 11,000 professional technicians around the world, we are always ready to provide the best service to our customers and help them solve their scientific problems. Our expertise in analytical testing, medical imaging, information technology and after-sales services, as well as in-depth market insights, helps our clients to explore and improve our living environment. In 2017, PerkinElmer received $2.3 billion and served more than 150 countries and territories. It is a member of the Standard & Poor's 500 Index and listed on the New York Stock Exchange under the symbol 1-877-PKI-NYSE. To learn more about PerkinElmer, please visit PerkinElmer's official website at
Disposable Trocar,Disposable Optical Trocar,Laparoscopic Bladeless Trocar,Disposable Laparoscopic Forceps
ZHEJIANG SHENDASIAO MEDICAL INSTRUMENT CO.,LTD. , https://www.sdsmedtools.com